Callan Family Office LLC Purchases Shares of 10,800 Genmab A/S (NASDAQ:GMAB)

Callan Family Office LLC purchased a new stake in shares of Genmab A/S (NASDAQ:GMAB) in the fourth quarter, according to the company in its most recent disclosure with the SEC. The institutional investor purchased 10,800 shares of the company’s stock, valued at approximately $225,000.

A number of other hedge funds and other institutional investors have also bought and sold shares of GMAB. Two Sigma Advisers LP raised its position in Genmab A/S by 84.1% during the 3rd quarter. Two Sigma Advisers LP now owns 615,100 shares of the company’s stock valued at $14,996,000 after purchasing an additional 280,900 shares during the last quarter. ABC Arbitrage SA bought a new position in Genmab A/S during the 4th quarter valued at approximately $3,692,000. AIMZ Investment Advisors LLC bought a new position in Genmab A/S during the 4th quarter valued at approximately $3,525,000. Raymond James Financial Inc. purchased a new position in shares of Genmab A/S during the 4th quarter worth approximately $2,463,000. Finally, Y Intercept Hong Kong Ltd grew its holdings in shares of Genmab A/S by 371.0% during the 4th quarter. Y Intercept Hong Kong Ltd now owns 73,696 shares of the company’s stock worth $1,538,000 after acquiring an additional 58,048 shares during the period. Institutional investors own 7.07% of the company’s stock.

Genmab A/S Stock Down 7.8 %

Genmab A/S stock opened at $20.26 on Wednesday. The company has a market capitalization of $13.41 billion, a P/E ratio of 11.64, a PEG ratio of 2.65 and a beta of 0.98. The stock’s 50 day moving average is $21.29 and its 200 day moving average is $22.54. Genmab A/S has a twelve month low of $18.64 and a twelve month high of $31.88.

Genmab A/S (NASDAQ:GMAB) last issued its earnings results on Wednesday, February 12th. The company reported $0.57 EPS for the quarter, beating the consensus estimate of $0.28 by $0.29. Genmab A/S had a return on equity of 16.78% and a net margin of 36.30%. As a group, equities analysts expect that Genmab A/S will post 1.45 EPS for the current year.

Wall Street Analyst Weigh In

A number of research analysts have weighed in on the company. Leerink Partnrs upgraded Genmab A/S from a “hold” rating to a “strong-buy” rating in a report on Thursday, February 13th. Truist Financial reduced their target price on Genmab A/S from $50.00 to $45.00 and set a “buy” rating on the stock in a report on Tuesday. Sanford C. Bernstein upgraded Genmab A/S from a “strong sell” rating to a “hold” rating in a report on Friday, December 20th. William Blair upgraded Genmab A/S from a “market perform” rating to an “outperform” rating in a report on Tuesday. Finally, HC Wainwright reiterated a “buy” rating and set a $50.00 target price on shares of Genmab A/S in a report on Thursday, January 23rd. Four research analysts have rated the stock with a hold rating, eight have issued a buy rating and one has issued a strong buy rating to the stock. Based on data from MarketBeat, the stock currently has a consensus rating of “Moderate Buy” and a consensus target price of $41.33.

About Genmab A/S

Genmab A/S develops antibody therapeutics for the treatment of cancer and other diseases primarily in Denmark. The company markets DARZALEX, a human monoclonal antibody for the treatment of patients with multiple myeloma (MM); teprotumumab for the treatment of thyroid eye disease; and Amivantamab for advanced or metastatic gastric or esophageal cancer and NSCLC.